Related Experiment Videos
An immune cell-selective interleukin 4 agonist
A B Shanafelt1, C P Forte, J J Kasper
1Bayer Corporation, Pharmaceutical Division, Biotechnology, 800 Dwight Way, Berkeley, CA 94710, USA. Shanafelt.B@bayer.com
Summary
Researchers engineered a novel Interleukin-4 (IL-4) variant, IL-4/R121E, that selectively targets immune cells like T cells, sparing endothelial cells. This discovery offers potential for treating autoimmune diseases.
Area of Science:
- Immunology
- Molecular Biology
- Cytokine Research
Background:
- Interleukin-4 (IL-4) is a pleiotropic cytokine with diverse cellular targets.
- Distinct IL-4 receptor (IL-4R) complexes exist on different cell types: T cells utilize IL-4Ralpha/IL-2Rgamma (class I), while endothelial cells use IL-4Ralpha/IL-13Ralpha (class II).
Purpose of the Study:
- To develop IL-4 variants with cell-type selectivity based on differential IL-4R expression.
- To investigate the potential therapeutic applications of such selective IL-4 variants.
Main Methods:
- Generation of IL-4 muteins by substituting regions interacting with IL-2Rgamma.
- Evaluation of mutein activity in T cell and endothelial cell assays.
- Receptor binding studies to confirm interaction profiles.
Main Results:
- The IL-4/R121E mutein demonstrated complete biological selectivity for T cells, B cells, and monocytes.
- IL-4/R121E showed no activity on endothelial cells.
- Binding studies confirmed IL-4/R121E interacts with IL-2Rgamma but not IL-13Ralpha, acting as an antagonist for IL-4 on endothelial cells.
Conclusions:
- IL-4/R121E exhibits a unique activity profile, selectively targeting immune cells.
- The selective nature of IL-4/R121E suggests its potential utility in treating autoimmune diseases by modulating specific immune responses.